Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-088514 · Präparat HOS-083663
7
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
ANTIFUNGALS
Fluconazole/Lamivudine Interaction not studied. As only limited data are
Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical
(400 mg once daily/200 mg significance is not known.
thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Lamivudine Interaction not studied. Insufficient data to
Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage
mg once daily/200 mg thrice adjustment.
daily) (UGT induction)
ANTICONVULSANTS
Phenobarbital/Lamivudine Interaction not studied. Insufficient data to
Phenobarbital/Zidovudine Interaction not studied. recommend dosage
adjustment.
Potential to slightly decrease
zidovudine plasma
concentrations through UGT
induction.
Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin
Phenytoin/Zidovudine Phenytoin AUC concentrations.
Valproic acid/Lamivudine Interaction not studied. As only limited data are
Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical
(250 mg or 500 mg thrice significance is not known.
daily/100 mg thrice daily)
(UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS)
Ranitidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely.
Cimetidine eliminated only in
part by renal organic cation
transport system.
Cimetidine/Zidovudine Interaction not studied.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied Therefore the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended
intracellular phosphorylation of (see section 4.4)
cladribine leading to a potential
risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) phenobarbital (HOS-085617) valproic acid (HOS-088515) cimetidine (HOS-085835) histamine (HOS-088516) fluconazole (HOS-087945) ranitidine (HOS-085660) phenytoin (HOS-084531) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 80bfcdbc676c074809992c973802a382b624f4a50bfeaaede637578173acc0cf · Zeichen 3740–7470 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090627 · Präparat HOS-084095
No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the
following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine,
prednisolone, and trimethoprim/sulfamethoxazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) prednisolone (HOS-086337) nifedipine (HOS-086289) trimethoprim (HOS-085184) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) digoxin (HOS-086172) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 0561145e72ae08336c293749a32c9afef82d758d8dcade48e65d208f6748281b · Zeichen 6798–7049 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090690 · Präparat HOS-084095
No clinically significant pharmacokinetic interaction was observed between sirolimus and any of the
following substances: acyclovir, atorvastatin, digoxin, glibenclamide, methylprednisolone, nifedipine,
prednisolone, and trimethoprim/sulfamethoxazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) prednisolone (HOS-086337) nifedipine (HOS-086289) trimethoprim (HOS-085184) atorvastatin (HOS-086304) methylprednisolone (HOS-088374) digoxin (HOS-086172) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 0561145e72ae08336c293749a32c9afef82d758d8dcade48e65d208f6748281b · Zeichen 6745–6996 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-108561 · Präparat HOS-093047
8
Stavudine/Zidovudine In vitro antagonism of anti-HIV
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Abacavir Interaction not studied. As only limited data available
Atovaquone/Lamivudine Interaction not studied. the clinical significance is
Atovaquone/Zidovudine Zidovudine AUC 33% unknown.
(750 mg twice daily with Atovaquone AUC
food/200 mg thrice daily)
Clarithromycin/Abacavir Interaction not studied. Separate administration of
Clarithromycin/Lamivudine Interaction not studied. Trizivir and clarithromycin by
Clarithromycin/Zidovudine Zidovudine AUC 12% at least 2 hours
(500 mg twice daily/100 mg
every 4 hours)
Trimethoprim/sulfamethoxazole Interaction not studied. No Trizivir dosage adjustment
(Co-trimoxazole)/Abacavir necessary, unless patient has
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% renal impairment (See Section
(Co-trimoxazole)/Lamivudine 4.2).
(160mg/800mg once daily for 5 Trimethoprim: AUC
days/300mg single dose) Sulfamethoxazole: AUC When concomitant
administration with co-
(organic cation transporter trimoxazole is warranted,
inhibition) patients should be monitored
Trimethoprim/sulfamethoxazole Interaction not studied. clinically. High doses of
(Co-trimoxazole)/Zidovudine trimethoprim/
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) atovaquone (HOS-086266) trimethoprim (HOS-085184) stavudine (HOS-088080) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 71bfdfc92b9301a18965d48965dbae21382ab47ace7b98ce7ba0a04318a98c78 · Zeichen 2506–4852 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26
HOS-108940 · Präparat HOS-093083
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of
contraception must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after
levothyroxine. starting and/or ending
lopinavir/ritonavir treatment.
Vasodilating agents
25
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should
AUC: ↑ 5-fold be closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of co-administration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) methadone (HOS-086198) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8d752c4274572732732b0956ff6ff26c5cf23921c5ef2d225aedad5e185afa6d · Zeichen 59817–63890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 61
HOS-109024 · Präparat HOS-093083
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone (TSH)
reported indicating a potential should be monitored in patients
interaction between ritonavir treated with levothyroxine at least the
containing products and first month after starting and/or
levothyroxine. ending lopinavir/ritonavir treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with bosentan.
concentrations may decrease due When Kaletra is administered
to CYP3A4 induction by concomitantly with bosentan, the
bosentan. efficacy of the HIV therapy should
be monitored and patients should be
Bosentan: closely observed for bosentan
AUC: ↑ 5-fold toxicity, especially during the first
Cmax: ↑ 6-fold week of co-administration.
Initially, bosentan Cmin: ↑ by
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and P-gp with Kaletra is not recommended
inhibition by lopinavir/ritonavir. (see section 4.4 and refer to riociguat
SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 65f5a6f4d7302840533b08e744ce8d52c7c6cce98bf349aa71cfb302b25446dd · Zeichen 59068–61276 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 96–97
HOS-109102 · Präparat HOS-093083
96
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after starting
levothyroxine. and/or ending lopinavir/ritonavir
treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should be
AUC: ↑ 5-fold closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of coadministration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage eb717f7573e257a0db9660c2692fa6be3f81b8ac5b4c1043b1f49219b74ffa31 · Zeichen 58967–62731 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-113477 · Präparat HOS-093937
Drugs by Therapeutic Area Interaction Recommendation concerning
Geometric mean change (%) co-administration
(Possible mechanism)
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine /Abacavir Interaction not studied. No dosage adjustment
Didanosine/Lamivudine Interaction not studied. necessary.
Zidovudine/Abacavir Interaction not studied
Zidovudine/Lamivudine Lamivudine: AUC
Zidovudine 300 mg single dose Zidovudine : AUC
Lamivudine 150 mg single dose
Emtricitabine/Lamivudine Due to similarities, Kivexa
should not be administered
concomitantly with other
cytidine analogues, such as
emtricitabine.
ANTI-INFECTIVE PRODUCTS
Trimethoprim/sulfamethoxazole Interaction not studied. No Kivexa dosage adjustment
(Co-trimoxazole)/Abacavir necessary.
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40%
(Co-trimoxazole)/Lamivudine When concomitant
(160 mg/800 mg once daily for Trimethoprim: AUC administration with
5 days/300 mg single dose) Sulfamethoxazole: AUC co-trimoxazole is warranted,
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) didanosine (HOS-085836) zidovudine (HOS-085837) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 3b23f2886f7d80d744304e64283fcb23c64e14afd5a52f5e8622a5373e4f7cc1 · Zeichen 1544–3217 im Abschnitt
Wechselwirkungen · Kivexa
Kivexa 600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-113478 · Präparat HOS-093937
7
patients should be monitored
(organic cation transporter clinically. High doses of
inhibition) trimethoprim/
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided
ANTIMYCOBACTERIALS
Rifampicin/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations
through UGT induction.
Rifampicin/Lamivudine Interaction not studied.
ANTICONVULSANTS
Phenobarbital/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations
through UGT induction.
Phenobarbital/Lamivudine Interaction not studied.
Phenytoin/Abacavir Interaction not studied. Insufficient data to recommend
dosage adjustment.
Potential to slightly decrease
abacavir plasma concentrations Monitor phenytoin
through UGT induction. concentrations.
Phenytoin/Lamivudine Interaction not studied.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184) phenobarbital (HOS-085617) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T12:00:00Z · SHA-256 014b022d5230b58f7efa74f9573b1c2e42d28f6a3d171aa8848bc0f8c92c1380 · Passage 387827645b1a19ba72bcdce583c6ff15cfaff9ba9910317f65a1827bc65c4f3b · Zeichen 3272–5207 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-116792 · Präparat HOS-094481
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Grapefruit or grapefruit juice May increase tacrolimus whole Avoid grapefruit or grapefruit
blood trough concentrations and juice.
increase the risk of serious adverse
reactions (e.g., neurotoxicity, QT
prolongation) [see section 4.4].
Ciclosporin May increase tacrolimus whole The simultaneous use of
blood trough concentrations. In ciclosporin and tacrolimus
addition, synergistic/additive should be avoided [see
nephrotoxic effects can occur. section 4.4].
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus
nephrotoxic or neurotoxic neurotoxic effects of tacrolimus. with drugs known to have
effects: nephrotoxic effects should be
aminoglycosides, gyrase avoided. When co-
inhibitors, vancomycin, administration cannot be
sulfamethoxazole + avoided, monitor renal
trimethoprim, NSAIDs, function and other side effects
ganciclovir, acyclovir, and adjust tacrolimus dose if
amphotericin B, ibuprofen, needed.
cidofovir, foscarnet
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ibuprofen (HOS-087884) amphotericin B (HOS-109312) trimethoprim (HOS-085184) cidofovir (HOS-110482) grapefruit juice (HOS-088787) vancomycin (HOS-110486) ganciclovir (HOS-085194) acyclovir (HOS-088527)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage b0395308050c5d9d3dab6530a2530819d6fdce6a20dc173d21940107d84f6ae3 · Zeichen 1941–3853 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 13
HOS-116841 · Präparat HOS-094481
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing
hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or
spironolactone) should be avoided (see section 4.4). Care should be taken when tacrolimus is co-
administered with other agents that increase serum potassium, such as trimethoprim and cotrimoxazole
(trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a potassium-sparing diuretic like
amiloride. Close monitoring of serum potassium is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) amiloride (HOS-089052) triamterene (HOS-089051) trimethoprim (HOS-085184) potassium (HOS-086929) spironolactone (HOS-112481)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 30e6eeb2317cdee4b7657b83f2d6f0c944b78efdd91aa2523ea6b7ddcf01974a · Zeichen 16837–17392 im Abschnitt
Wechselwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-209321 · Präparat HOS-154301
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4218–4301 im Abschnitt
Wechselwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-209396 · Präparat HOS-154301
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4217–4300 im Abschnitt
Wechselwirkungen · Myfenax
Myfenax 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-209466 · Präparat HOS-154315
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:04:00Z · SHA-256 1eac250c72b4f0a4fe3012df5ca65f8295e08fe953b2900f2e41cf74ecbe8efc · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4218–4301 im Abschnitt
Wechselwirkungen · Myfenax
Myfenax 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-209535 · Präparat HOS-154315
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:04:00Z · SHA-256 1eac250c72b4f0a4fe3012df5ca65f8295e08fe953b2900f2e41cf74ecbe8efc · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4218–4301 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 10–11
HOS-209742 · Präparat HOS-154375
10
Medicinal products which have effects on tacrolimus
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
Grapefruit or grapefruit juice May increase tacrolimus Avoid grapefruit or grapefruit
whole blood trough juice.
concentrations and increase
the risk of serious adverse
reactions (e.g., neurotoxicity,
QT prolongation) [see
section 4.4].
Ciclosporin May increase tacrolimus The simultaneous use of
whole blood trough ciclosporin and tacrolimus should
concentrations. In addition, be avoided [see section 4.4].
synergistic/additive
nephrotoxic effects can
occur.
Products known to have May enhance nephrotoxic or Concurrent use of tacrolimus with
nephrotoxic or neurotoxic neurotoxic effects of drugs known to have nephrotoxic
effects: tacrolimus. effects should be avoided. When
aminoglycosides, gyrase co-administration cannot be
inhibitors, vancomycin, avoided, monitor renal function
sulfamethoxazole + and other side effects and adjust
trimethoprim, NSAIDs, tacrolimus dose if needed.
ganciclovir, acyclovir,
amphotericin B, ibuprofen
cidofovir, foscarnet
Strong CYP3A4 inhibitors: May increase tacrolimus It is recommended that
antifungal agents (e.g., whole blood trough concomitant use should be
ketoconazole, itraconazole, concentrations and increase avoided. If co-administration of a
posaconazole, voriconazole), the risk of serious adverse strong CYP3A4 inhibitor is
the macrolide antibiotics reactions (e.g., unavoidable, consider omitting
(e.g., telithromycin, nephrotoxicity, the dose of tacrolimus the day the
troleandomycin, neurotoxicity, QT strong CYP3A4 inhibitor is
clarithromycin, josamycin), prolongation) which requires initiated. Reinitiate tacrolimus the
HIV protease inhibitors (e.g., close monitoring [see next day at a reduced dose based
ritonavir, nelfinavir, section 4.4]. on tacrolimus blood
saquinavir), HCV protease Rapid and sharp increases in concentrations. Changes in both
inhibitors (e.g., telaprevir, tacrolimus levels may occur, tacrolimus dose and/or dosing
boceprevir, and the as early as within 1-3 days frequency should be
combination of ombitasvir after co-administration, individualized and adjusted as
and paritaprevir with despite immediate reduction needed based on tacrolimus
ritonavir, when used with and of tacrolimus dose. Overall trough concentrations, which
without dasabuvir), tacrolimus exposure may should be assessed at initiation,
nefazodone, the increase > 5 fold. When monitored frequently throughout
pharmacokinetic enhancer ritonavir combinations are (starting within the first few days)
cobicistat and the kinase co-administered, tacrolimus and re-evaluated on and after
inhibitors idelalisib, ceritinib. exposure may increase > 50 completion of the CYP3A4
Strong interactions have also fold. inhibitor. Upon completion,
been observed with the Nearly all patients may appropriate dose and dosing
macrolide antibiotic require a reduction in frequency of tacrolimus should be
erythromycin tacrolimus dose and guided by tacrolimus blood
temporary interruption of concentrations. Monitor renal
tacrolimus may also be function, ECG for QT
necessary. prolongation, and other side
effects closely.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): foscarnet (HOS-110484) sulfamethoxazole (HOS-084533) ceritinib (HOS-086215) josamycin (HOS-113844) nefazodone (HOS-084519) nelfinavir (HOS-084520) ibuprofen (HOS-087884) protease (HOS-085623) amphotericin B (HOS-109312) trimethoprim (HOS-085184) ketoconazole (HOS-084513) cobicistat (HOS-088111) cidofovir (HOS-110482) grapefruit juice (HOS-088787) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) vancomycin (HOS-110486) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) ganciclovir (HOS-085194) paritaprevir (HOS-110301) acyclovir (HOS-088527) posaconazole (HOS-085622) idelalisib (HOS-116811)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 84292deca9b273b57aafc577a96618c8f1b67362b0e5f3bec58af5bfd6d618af · Zeichen 1995–6929 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 14
HOS-209775 · Präparat HOS-154375
As tacrolimus treatment may be associated with hyperkalaemia, or may increase pre-existing
hyperkalaemia, high potassium intake, or potassium-sparing diuretics (e.g. amiloride, triamterene, or
spironolactone) should be avoided (see section 4.4). Care should be taken when tacrolimus is
co-administered with other agents that increase serum potassium, such as trimethoprim and
cotrimoxazole (trimethoprim/sulfamethoxazole), as trimethoprim is known to act as a
potassium-sparing diuretic like amiloride. Close monitoring of serum potassium is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) amiloride (HOS-089052) triamterene (HOS-089051) trimethoprim (HOS-085184) potassium (HOS-086929) spironolactone (HOS-112481)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage aac5d9318a66c91e23e4c1fc78590754f2d30cc155ff58f481f62c0b5cad0dff · Zeichen 17014–17568 im Abschnitt
Wechselwirkungen · Lamivudine Teva Pharma B.V.
Lamivudine Teva Pharma B.V. 150 mg film-coated tablets Lamivudine Teva Pharma B.V. 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-211901 · Präparat HOS-154784
Administration of trimethoprim/sulfamethoxazole 160 mg/800 mg results in a 40% increase in
lamivudine exposure, because of the trimethoprim component; the sulfamethoxazole component did
not interact. However, unless the patient has renal impairment, no dosage adjustment of lamivudine is
necessary (see section 4.2). Lamivudine has no effect on the pharmacokinetics of trimethoprim or
sulfamethoxazole. When concomitant administration is warranted, patients should be monitored
clinically. Co-administration of lamivudine with high doses of co-trimoxazole for the treatment of
Pneumocystis jirovecii pneumonia (PCP) and toxoplasmosis should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-21T15:48:00Z · SHA-256 20f7e52b86e41eb238a7c02628d41f826d204c97eddc200b9de9d5dfd73ec34c · Passage e8a7506dd7614242257eac5ae343ff4aff7beba39b9f41538cbccef23f1853b3 · Zeichen 139–791 im Abschnitt
Wechselwirkungen · Myclausen
Myclausen 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-212912 · Präparat HOS-155006
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T14:45:00Z · SHA-256 5212e91cac7f54413fc4524ec82e254c35610b87ec825a71d5d295c67a8c8df9 · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4168–4251 im Abschnitt
Wechselwirkungen · Myclausen
Myclausen 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 25
HOS-212968 · Präparat HOS-155006
Trimethoprim/sulfamethoxazole
No effect on the bioavailability of MPA was observed.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) trimethoprim (HOS-085184)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T14:45:00Z · SHA-256 5212e91cac7f54413fc4524ec82e254c35610b87ec825a71d5d295c67a8c8df9 · Passage f5eb13e5f8adc0c1c8ff86878511667093f162d5c256caf8cf1d9351c05f64e8 · Zeichen 4168–4251 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.